When cystic fibrosis is not the answer: reclassification and follow-up of children with an unresolved diagnosis after extended CFTR gene analysis


Akca Dinç G., TUĞCU G. D., Bilgiç I., Kürtül Çakar M., Aktemur Ünlü A., Yetişgin H., ...Daha Fazla

European Journal of Pediatrics, cilt.185, sa.11, 2026 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 185 Sayı: 11
  • Basım Tarihi: 2026
  • Doi Numarası: 10.1007/s00431-026-07542-w
  • Dergi Adı: European Journal of Pediatrics
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CINAHL, EMBASE, MEDLINE, Academic Search Ultimate (EBSCO), Biomedical Reference Collection: Corporate Edition (EBSCO), Health Research Premium Collection (ProQuest)
  • Anahtar Kelimeler: CF carrier, CFSPID, CFTR-related disorder, Cystic fibrosis, Newborn screening, Sweat chloride
  • Ankara Yıldırım Beyazıt Üniversitesi Adresli: Evet

Özet

CFTR-related metabolic syndrome (CRMS)/CF screen-positive inconclusive diagnosis (CFSPID), cystic fibrosis (CF) carrier, and CFTR-related disorder (CFTR-RD) are assigned both after newborn blood screening (NBS) and, in children who were screen-negative or never screened, after a later diagnostic work-up; longitudinal data from low-F508del populations remain scarce. We describe the classification and follow-up of children with an unresolved CFTR diagnosis. We reviewed every child evaluated for CRMS/CFSPID, CF carrier status or a CFTR-RD at a single center in 2018–2025, tested locally by CFTR sequencing and multiplex ligation-dependent probe amplification (MLPA) or referred through NBS. All diagnoses, including those of children already labeled as CF, were reassessed against current criteria. Diagnoses followed 2017 and 2021 consensus criteria. We described serial sweat chloride test (SCT) changes over time where repeated measurements were available. Of 563 children, 20 (3.6%) formed the cohort after excluding confirmed CF (74, 13.1%) and single non-CF-variant carriers (369, 65.5%): 7 CRMS/CFSPID, 11 CF carriers, 1 CFTR-related disorder (CFTR-RD), 1 unclassifiable. Five of 79 children previously diagnosed with CF (6.3%) were reclassified after variant reinterpretation; one had received CFTR modulator therapy, which was safely withdrawn. F508del was present in 5/20 (25%), all of them CF carriers. No child progressed to CF; nutrition, exocrine pancreatic function, and chest radiography were largely preserved. Serial SCT rose over time in six children across diagnostic groups, although in half of them only two measurements were available. Two sisters with one complex genotype diverged: one unclassifiable, with the largest rise in SCT (from 12.9 to 52 mmol/L), the other with CFTR-RD and recurrent pancreatitis. Conclusion: In this cohort from a low-F508del population, extended CFTR analysis reclassified most children away from CF, to CRMS/CFSPID or carrier status. No child progressed to CF during follow-up, although the SCT rose in a subset and five children were reclassified from a previous CF diagnosis. Structured follow-up with periodic reinterpretation of variants may benefit selected children; the role of CFTR modulators in this setting remains undefined. (Table presented.)